AzTrials
AzTrials

Flutter, AtrialSECTIONNCT06691074

Cavo-Tricuspid Isthmus Block Durability After Pulsed Electric Field Ablation

A study testing Catheter ablation of cavotricuspid isthmus using flower configuration of the Farapulse catheter and Catheter ablation of cavotricuspid isthmus using basket configuration of the Farapulse catheter in people with Flutter, Atrial and Cavotricuspid Isthmus Dependent Right Atrial Flutter, run by Institute for Clinical and Experimental Medicine at 1 site in Czechia.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This study seeks to assess the acute durability of the CTI block when PEF energy is used. Second goal is to establish the optimal waiting time for the conduction recovery after PEF CTI ablation and to assess the utility of routine adenosine testing for dormant conduction. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Catheter ablation of cavotricuspid isthmus using flower configuration of the Farapulse catheter and Catheter ablation of cavotricuspid isthmus using basket configuration of the Farapulse catheter
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
150 participants
Where
1 siteCzechia
Study dates
16 Sep 2024to 31 Dec 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • patients with paroxysmal AF undergoing PVI by PEF energy with documented typical atrial flutter or patients with persistent AF in whom catheter ablation of CTI is planned as a part of a complex procedure
  • Age ≥ 18 years at the time of study enrollment
  • Signed informed consent

Who cannot join

  • - LA diameter \> 65 mm (measured in the parasternal long-axis view)
  • History of CTI ablation in the past
  • History of cardiac valve surgery
  • Significant valvular defect
  • Age below 18 years
  • Pregnancy, breastfeeding
Show all 14Show fewer
  • Any disease with a life expectancy \<1 year
  • Uncorrected congenital heart disease or valvular obstruction
  • Active myocarditis
  • Untreated hypothyroidism or hyperthyroidism
  • Recipient of any major organ transplant (e.g., lung, liver, heart)
  • HIV positivity with a survival expectancy of less than five years due to HIV
  • Chronic dialysis treatment
  • Unwillingness to participate.

Trial locations and contacts

1 site in 1 country.

Czechia1 site, 1 recruiting
  • Institute for Clinical and Experimental Medicine

    Prague, Prague, 14200

    Predrag Stojadinovic, MD, +420 731532634, stop@gmail.com

    Recruiting

Other trials in Czechia

About this study

Official title: Systematic Assessment of the Acute Cavo-Tricuspid Isthmus Block Durability After Pulsed Electric Field Ablation

This study seeks to assess the acute durability of the CTI block when PEF energy is used. Second goal is to establish the optimal waiting time for the conduction recovery after PEF CTI ablation and to assess the utility of routine adenosine testing for dormant conduction. Moreover, this study aims to investigate the differences in acute efficacy and adverse events (hemolysis, coronary vasospasm) between the two available configurations (basket or flower) of the pentaspline Farawave catheter (Farapulse-Boston Scientific Inc, USA).

Read the detailed description

Background Cavo-tricuspid isthmus (CTI) ablation is commonly performed as a concomitant procedure in patients undergoing pulmonary vein isolation (PVI) or more extensive left atrial ablations for the treatment of atrial fibrillation (AF). While the acute and long-term resumption of conduction in the CTI after radiofrequency ablation has already been investigated, the acute durability of the CTI block created by pulsed-electric field (PEF) energy has not been systematically evaluated.

Study population A prospective, multicentric randomized study conducted at high-volume centre with the routine use of intracardiac echocardiography (ICE). A total of 150 consecutive patients with paroxysmal AF undergoing PVI by PEF energy with documented typical atrial flutter or patients with persistent AF in whom catheter ablation of CTI is planned as a part of a complex procedure will be enrolled in the study.

Methods Procedures will be performed under general anaesthesia (GA) or deep analgo-sedation and on uninterrupted anticoagulation. One decapolar catheter will be introduced into the coronary sinus (CS). A duodecapolar catheter will be placed in the right atrium around the tricuspid annulus. A single transseptal puncture will be performed under ICE guidance. After obtaining the left atrial (LA) access, the Faradrive sheath will be redrawn into the right atrium. Patient presenting with AF or other atrial arrhythmias at the beginning of the procedure will be cardioverted. Prior to initiating pulsed field ablation (PFA) on the CTI, sublingual nitrates will be administered in the form of two sprays of nitroglycerin at a dose of 0.30 mg per spray. The CTI ablation will be performed during regular atrial pacing from the proximal CS at a cycle length of 600 ms. Sequential applications of PEF energy will be delivered in an overlapping fashion from the tricuspid annulus to the inferior cava vein under ICE guidance. Patients will be randomized in a 1:1 ratio based on the configuration of the catheter used to achieve CTI block (basket vs. flower). In both groups, three applications will be deployed at each spot. If acute block is not achievable using the randomized configuration, patients will be ablated using the other configuration and any additional lesions per operator discretion to achieve acute block. After demonstrating the bidirectional CTI block with standard pacing maneuvers (differential pacing from duodecapolar catheter and proximal CS), the surface electrocardiogram (ECG) will be analyzed across all 12 leads to evaluate for the presence of ST segment elevation. The left atrial procedure will be then performed during regular atrial pacing from the proximal CS. An eventual conduction recovery over the CTI and the corresponding time since the last ablation on the CTI will be recorded. Dormant conduction over the CTI will be assessed using an I.V. bolus of 12-18 mg of adenosine during continuous atrial pacing immediately after the confirmation of the CTI block and at the end of the procedure. The total waiting time and number of PEF applications on the CTI will be documented. At the end of the procedure, additional PEF applications per operator discretion on the CTI will be delivered if needed.

Sample size While no clear data on comparison of different Farapulse configurations on CTI are available, with 150 patients in the trial at a given expected acute success rate of 85 % in basket configuration given our clinical experience and a noninferiority design, a noninferiority margin of 15% at a power level of 82% can be tested.

Plasmatic biomarkers Venous blood samples for the assessment of plasma biomarkers (free hemoglobin [fHb], lactate dehydrogenase [LDH], total bilirubin, and haptoglobin) will be collected at two time points: before the procedure (T1) and after CTI isolation before LA ablation (T2).

Clinical implications

  1. Achieving CTI block at the beginning of the catheter ablation of AF may provide sufficient waiting time to verify the durability of the block on TCI and thus enhance the long-term clinical effect of the procedure.
  2. An absence of adenosine-induced CTI reconnection immediately after the CTI block could predict the durability of block at the end of the procedure and obviate the need for prolonged waiting period.
  3. The use of the flower configuration to achieve CTI block could be associated with a non-inferior acute success rate and lower incidence of hemolysis.
Being tested
Catheter ablation of cavotricuspid isthmus using flower configuration of the Farapulse catheter, Catheter ablation of cavotricuspid isthmus using basket configuration of the Farapulse catheter
Keywords
Pulsed Electric Field, Cavo-tricuspid Isthmus, Biderectional Block
Medical subject headings
Atrial Flutter

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Catheter ablation of cavotricuspid isthmus using flower configuration of the Farapulse catheterProcedure or surgery

    catheter ablation

  • Catheter ablation of cavotricuspid isthmus using basket configuration of the Farapulse catheterProcedure or surgery

    Catheter ablation of cavotricuspid isthmus using basket configuration of the Farapulse catheter

Study groups in NCT06691074
Study groupRoleWhat they receive
Flower configurationActive comparatorAblation of the CTI using a Farapulse catheter in flower configuration
Receives: Procedure: Catheter ablation of cavotricuspid isthmus using flower configuration of the Farapulse catheter
Basket configurationActive comparatorAblation of the CTI using a Farapulse catheter in basket configuration
Receives: Procedure: Catheter ablation of cavotricuspid isthmus using basket configuration of the Farapulse catheter

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The acute durability of the CTI block

    The primary goal of this study is to assess the acute durability of the CTI block when PEF energy is used. The bidirectional block on the CTI will be demonstrated with standard pacing manoeuvres (differential pacing from duodecapolar catheter and proximal CS).

    Measured: During the ablation procedure

Secondary outcomes (4)
  1. The optimal waiting time for the conduction recovery after PEF CTI ablation

    Second goal is to establish the optimal waiting time for the conduction recovery after PEF CTI ablation.

    Measured: During the procedure

  2. The utility of routine adenosine testing for dormant conduction on the CTI

    Dormant conduction over the CTI will be assessed using an I.V. bolus of 12-18 mg of adenosine during continuous atrial pacing immediately after the confirmation of the CTI block and at the end of the procedure.

    Measured: During the ablation procedure.

  3. Concentration of plasma free haemoglobin

    Plasma biomarker of hemolysis (free haemoglobin [fHb]) will be measured at two time points: before the procedure (T1) and after CTI isolation before LA ablation (T2). Levels of fHb will be compared among the study groups.

    Measured: During the ablation procedure

  4. The presence of the coronary vasospasm

    The surface electrocardiogram (ECG) will be analyzed across all 12 leads to evaluate for the presence of ST segment elevation (i.e. signs of the coronary vasospasm) after the CTI ablation.

    Measured: During the ablation procedure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Nov 2024
  2. Study start16 Sep 2024
  3. Primary completion31 Dec 2025 (estimated)
  4. Study completion31 Dec 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
150 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06691074
Sponsor's protocol ID
28518/24; A-24-24
Other IDs
SECTION trial
Acronym
SECTION
Status last verified
Sep 2024
First submitted
16 Sep 2024
Last updated
15 Nov 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: all IPD collected throughout the trial

Publications

  • Morales G, Darrat YH, Lellouche N, Kim SM, Butt M, Bidwell K, Lippert W, Ogunbayo G, Hamon D, Di Biase L, Natale A, Parrott K, Elayi CS. Use of adenosine to shorten the post ablation waiting period for cavotricuspid isthmus-dependent atrial flutter. J Cardiovasc Electrophysiol. 2017 Aug;28(8):876-881. doi: 10.1111/jce.13233. Epub 2017 May 29.

    PubMed 28429528
  • Yoneda ZT, Shoemaker MB, Richardson T, Crawford D, Kanagasundram A, Shen S, Estrada JC, Holmes B, Lugo R, McHugh J, Saavedra P, Crossley G 3rd, Ellis CR, Montgomery JA, Michaud GF. Conduction Recovery After Cavotricuspid Isthmus Ablation When Performed With or Without Concomitant Atrial Fibrillation Ablation. JACC Clin Electrophysiol. 2020 Aug;6(8):989-996. doi: 10.1016/j.jacep.2020.04.031.

    PubMed 32819535
  • Chen J, de Chillou C, Ohm OJ, Hoff PI, Rossvoll O, Andronache M, Sadoul N, Magnin-Poull I, Erga KS, Aliot E. Acute resumption of conduction in the cavotricuspid isthmus after catheter ablation in patients with common atrial flutter. Real-time evaluation and long-term follow-up. Europace. 2002 Jul;4(3):255-63. doi: 10.1053/eupc.2002.0243.

    PubMed 12134971

Questions about this trial

What is this clinical trial studying?

A study testing Catheter ablation of cavotricuspid isthmus using flower configuration of the Farapulse catheter and Catheter ablation of cavotricuspid isthmus using basket configuration of the Farapulse catheter in people with Flutter, Atrial and Cavotricuspid Isthmus Dependent Right Atrial Flutter, run by Institute for Clinical and Experimental Medicine at 1 site in Czechia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 15 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Czechia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The acute durability of the CTI block (time frame: During the ablation procedure). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06691074, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Nov 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in